BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019
Shots:
- The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg- SC) vs adalimumab (40mg- SC) on a background of MTX in 80 patients in a ratio (1:1) with moderate-to-severe RA seropositive for anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)
- The P-IV Early AMPLE study results: @24wks. ACR 20/50/70 responses (83/70/48 vs 63/45/30); ACR 20/50/70 with Shared Epitope positive (SE+) (28.6/31.5/27.6); DAS28-CRP remission <2.6 (27.4)- no new safety signals are observed
- Orencia is an immunomodulator act by disrupting the continuous cycle of T-cell activation that characterizes RA and indicated for RA- juvenile idiopathic arthritis & adult psoriatic arthritis (PsA) in the US
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com